Home
overview

As one of the worlds most prevalent chronic diseases, Asthma is set to exhaust already over-stretched healthcare budgets, driving the development of more cost-effective therapies. Similarly the market for Chronic Obstructive Pulmonary Disease (COPD), which affects 600million people world-wide, is set to double in size by the year 2011 due to an
ageing population and new product launches.

SMi’s Conference on Asthma & COPD will endeavour to address the latest developments in Asthma and COPD research, new targets in drug discovery and development and current unmet needs in both areas. The latest in the search for effective asthma and COPD therapeutics will be established with a review of company specific product pipelines. This
event will also project and investigate the future direction and value of the global asthma and COPD market.

Gain an insight from the key industry leaders in the field:

  • Dr John Warren, Medical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
  • Dr Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline
  • Dr Noel Snell, Global Clinical Expert, Respiratory Medicine, AstraZeneca
  • Dr Chris Compton, Executive Director, Clinical Research & Development, Pfizer
  • Dr Samuel Goldman, Director, Respiratory Disease, Wyeth
  • Dr David J Valacer, Director, Clinical Research, F. Hoffman-La Roche
  • Dr Dirk Bredenbröker, Head, Clinical Research, Pulmonology, ALTANA Pharma
  • Dr Stephan Stenglein, Medical Director, Clinical Programme Leader, Novartis
  • Alex Bell, Head, New Product Introduction, Respiratory Technology, Sanofi-Aventis
  • Dr Craig Conoscenti, Associate Director, Clinical & Scientific Affairs, Boehringer-Ingelheim
  • Dr Tim Higenbottam, Associate Director & Senior Principal Scientist, AstraZeneca

Key issues that will be addressed at the Conference include:

  • CURRENT TRENDS: Assess the latest trends in asthma and COPD, including an exploration of existing treatments, unmet clinical needs and future directions in therapy PRICING AND REIMBURSEMENT: Understand the latest pricing threats in Europe and the US, with a focus on differences, commonality and implications
  • REGULATIONS: A review and interpretation of regulatory guidelines for the development of drugs in asthma and COPD
  • PRECLINICAL AND CLINICAL BIOMARKERS: Identifying biomarkers in BAL
  • CURRENT AND FUTURE DRUGS FOR THE TREATMENT OF ASTHMA AND COPD: Hear about the latest effective drugs for the management of both asthma & COPD and the future impact of new treatments
  • NETWORKING OPPORTUNITIES: Meet the leaders in the field, make valuable contacts and learn from their experience and expertise

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Steven Kesten

Dr Steven Kesten, Therapeutic Area Director, Respiratory, Boehringer-Ingelheim

9:10 KEYNOTE ADDRESS

  • Changes in disease epidemiology
  • Understanding the disease pathophysiology
  • How good are current treatments?
  • Unmet needs – are they being addressed?
  • Novel directions in therapy
  • Dr Noel Snell

    Dr Noel Snell, Global Clinical Expert, Respiratory Medicine, AstraZeneca

    9:50 CURRENT TRENDS IN COPD EPIDEMIOLOGY

    Prof Neil Barnes

    Prof Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust

  • Reviewing the prevalence and severity of COPD
  • Assessing the awareness of COPD and related medical conditions
  • The diagnostics of patients with COPD
  • Patient education and compliance
  • Projections
  • Future treatments and developments in the area
  • 10:30 Morning Coffee

    10:50 REGULATORY GUIDELINES

    Dr John Warren

    Dr John Warren, Medical Assessor, Medicines and Healthcare products Regulatory Agency (MHRA)

  • CHMP guidelines for asthma
  • Differentiation between asthma and COPD
  • CHMP- guidelines for COPD
  • Key questions for the dossier - asthma
  • Key questions for the dossier - COPD
  • How to obtain further advice
  • 11:30 PRICING AND REIMBURSEMENT ISSUES

  • Direct and in-direct costs- inpatient hospitalisation/emergency room visits
  • Pricing threats- Europe vs US
  • Pricing strategies- EU, US and Japan
  • A look at differences, commonality and implications
  • Treatment cost analysis
  • Pricing data for key products in the major markets
  • Dr Ann-Katrin Gonschior

    Dr Ann-Katrin Gonschior, International Product Manager, ALTANA Pharma

    12:10 PRECLINICAL AND CLINICAL BIOMARKER DISCOVERY AND DEVELOPMENT

    Dr Samuel Goldman

    Dr Samuel Goldman, Director, Respiratory Disease, Wyeth

  • Identifying biomarkers in BAL from a preclinical model of segmental allergen challenge
  • Identifying biomarkers in peripheral blood from a preclinical model of segmental allergen challenge
  • Global gene expression analyses of peripheral blood from asthmatics: results from an asthma observational study
  • 12:50 Networking Lunch

    14:20 HOW TO MEASURE PATIENTS SYMPTOMS IN COPD TRIALS

    Dr Gonzalo de Miquel

    Dr Gonzalo de Miquel, Senior Medical Adviser, Almirall

  • Correlation between COPD symptoms and severity
  • How to measure and record COPD symptoms
  • Comparison of different COPD symtoms questionnaires
  • QoL and symtpoms in COPD trials
  • Utility of COPD symptoms-measures in clinical trials
  • 15:00 LUNG DESITOMETRY IN THE ASSESSMENT OF PROGRESSION OF COPD USING COMPUTED TOMOGRAPHY

    Dr Berend Stoel

    Dr Berend Stoel, Assistant Professor, Orthopaedics & Pulmonology Department, Leiden University Medical Center

  • Basic principles of densitometry with CT
  • Validation against pathology, pulmonary function and health status
  • Software for automatic quantification of lung density: PulmoCMS
  • CT standardization and optimisation
  • Quality control
  • 15:40 Afternoon Tea

    16:00 THE CLIINICAL DEVELOPMENT OF DRUGS FOR ASTHMA AND COPD

  • COPD develops as a result of tobacco smoke lung injury
  • Aberrant repair results in emphysema obliterative bronchiolitis and pulmonary vascular disease disease
  • Therapies directed at enhancing repair
  • Asthma is a result of a phenotype change in antigen handling
  • Treatment for asthma should alter this phenotype
  • Professor Tim Higenbottam

    Professor Tim Higenbottam, Associate Director & Senior Principal Scientist, AstraZeneca

    16:40 COMBINATION THERAPIES

    Dr Chris Compton

    Dr Chris Compton, Executive Director, Clinical Research & Development, Pfizer

  • Current therapies including bronchodilators and inhaled steroids
  • Proving the benefits of combination therapy
  • Efficacy and safety
  • Impact upon the management of asthma and COPD
  • Future combination therapies
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Philip Barr

    Dr Philip Barr, Chief Scientific Officer, Arriva Pharmaceuticals

    9:10 ANTICHOLINERGIC TREATMENT OF COPD

    Dr Craig Conoscenti

    Dr Craig Conoscenti, Associate Director, Clinical & Scientific Affairs, Boehringer-Ingelheim

  • Expiratory airflow limitation is the hallmark physiologic change of COPD
  • All major treatment guidelines recommend bronchodilators as the first-line treatment for the management of COPD
  • Anticholinergic bronchodilators impact a significant contributer to airflow limitation in COPD
  • 9:50 PHOSPHODIESTERASE -4 INHIBITORS- A NEW CLASS OF DRUG

    Stephan Witte

    Stephan Witte, Senior International Study Manager, ALTANA Pharma Deutschland GmbH

  • Pharmacological rationale for PDE4 as an important target in asthma and COPD therapy
  • PDE4 inhibitors targeting inflammation in asthma and COPD
  • Novel PDE4 inhibitors under clinical development
  • Assessing efficacy and safety of PDE4 inhibitors in phase I-III
  • Roflumilast as a PDE4 inhibitor under clinical development for asthma and COPD
  • 10:30 Morning Coffee

    11:00 MAXIMISING EFFICACY OF PHOSPHODIESTERASE -4 INHIBITORS IN COPD AND ASTHMA

    Dr Peter Schafer

    Dr Peter Schafer, Associate Director, Biology, Celgene Corporation

  • Mechanism of action in preclinical models of lung inflammation and asthma
  • Molecular profile of compounds vs therapeutic
  • Inhibition of airway hyperreactivity: role of bronchodilation
  • CC-10004 Phase I clinical data
  • Future development
  • 11:40 ASSESSING THE LATEST INHALED CORTICOSTEROIDS

    Dr Malcolm Johnson

    Dr Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline

  • The molecular mechanisms of corticosteroids
  • Clinical responses to corticosteroids and best usage
  • Limitations of therapy
  • Inhaled corticosteroids vs oral corticosteroids
  • Corticosteroids and combination therapies
  • Current research and development
  • Pipeline products for the treatment of asthma and COPD
  • 12:20 Networking Lunch

    13:50 INHALER DEVICES FOR THE MANAGEMENT OF ASTHMA AND COPD

    Alex Bell

    Alex Bell, Head, New Product Introduction, Respiratory Technology, Sanofi-Aventis

  • Inhaled therapy delivering broncholdilator and corticosteroids
  • Understand key developments in the pulmonary device sector
  • Analyse and determine the impact of liquid-based inhalers
  • Current inhaled drug delivery technology on the market including pressurised metered dose inhalers (pMDIs), drug powder inhalers (DPIs) and nebulisers
  • Effectiveness vs efficacy
  • Prevailing clinical guidelines
  • The future of inhaled technology
  • 14:30 A NOVEL FORMOTEROL MULTI-DOSE DRY POWDER INHALER FOR THE TREATMENT OF ASTHMA

    Dr Stephan Stenglein

    Dr Stephan Stenglein, Medical Director, Clinical Program Leader, Novartis

  • Clinical overview/unmet patient needs in asthma
  • Usefulness of MDDPIs
  • Clinical Data
  • Potential uses in COPD
  • 15:10 Afternoon Tea

    15:40 TECHNICAL DEVELOPMENT BEHIND THE MULTIPLE-DOSE DRY POWDER INHALER

    Dr Carsten Niederlaender

    Dr Carsten Niederlaender, Head, Technical Research Development & Production, SkyePharma

  • Worldwide development of the Skyehaler: what were the targets?
  • Improving medication delivery and patient compliance by design of the DPI: airflow actuation limit, respirable dose counter, dosing orientation and look out mechanism
  • Challenges and regulatory considerations on construction and plastic materials
  • Examples for DPI in vitro performance
  • 16:20 IMMUNE SYSTEM TARGETS IN THE TREATMENT OF ASTHMA

    Dr David J Valacer

    Dr David J Valacer, Director, Clinical Science, Hoffmann-La Roche Inc

  • Review advances in the understanding of the role of T cells in asthma pathophysiology
  • Describe the potential benefits and risks of targeting T cells as a new therapeutics approach for asthma
  • Case study: Daclizumab (Zenapax®)
  • Review the biology of daclizumab (Zenapa®), a humanized Anti-Tac (CD25) monoclonal
  • Review clinical responses to daclizumab therapy in asthma: phase I and II asthma trial results
  • Describe potential impact of daclizumab on the future treatment of asthma
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Mayfair Conference Centre

    17 Connaught Mews
    London W2 2EL
    United Kingdom

    Mayfair Conference Centre

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.